Literature DB >> 11274241

Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome.

D Maroeska W M Te Loo1, Victor W M VAN Hinsbergh2,3, Lambertus P W J VAN DEN Heuvel1, Leo A H Monnens1.   

Abstract

The epidemic form of hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in children and is characterized by a prodromal phase of sometimes bloody diarrhea. The role of verocytotoxin (VT)-producing Escherichia coli has been strongly implicated. Although antibodies against VT have been detected in the serum of patients with HUS, VT itself has never been detected in circulating blood. In this study, VT-2 was detected in the systemic circulation in 9 of 10 patients with the epidemic form of HUS. In those cases, VT-2 was bound exclusively to polymorphonuclear leukocytes (PMN). The detection of VT-2 bound to PMN was associated with the presence of diarrhea at the time the blood samples were obtained. The one patient for whom VT was not detected presented with atypical HUS. For 5 of the 10 patients with HUS who were studied, the time course of VT binding was analyzed; binding decreased in four patients. The finding of VT bound to PMN in the systemic circulation of patients with HUS is important for a clearer understanding of the pathogenesis of HUS and suggests new approaches for treatment in the future.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274241     DOI: 10.1681/ASN.V124800

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  36 in total

1.  Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome.

Authors:  Philipp A Lang; Ortraud Beringer; Jan P Nicolay; Oliver Amon; Daniela S Kempe; Tobias Hermle; Philipp Attanasio; Ahmad Akel; Richard Schäfer; Björn Friedrich; Teut Risler; Matthias Baur; Christoph J Olbricht; Lothar Bernd Zimmerhackl; Peter F Zipfel; Thomas Wieder; Florian Lang
Journal:  J Mol Med (Berl)       Date:  2006-04-19       Impact factor: 4.599

2.  Shiga toxin 2 and flagellin from shiga-toxigenic Escherichia coli superinduce interleukin-8 through synergistic effects on host stress-activated protein kinase activation.

Authors:  Dakshina M Jandhyala; Trisha J Rogers; Anne Kane; Adrienne W Paton; James C Paton; Cheleste M Thorpe
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

3.  CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation.

Authors:  James K Roche; Tiffany R Keepers; Lisa K Gross; Regina M Seaner; Tom G Obrig
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 4.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 5.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Shigatoxin-1 binding and receptor expression in human kidneys do not change with age.

Authors:  Zuhal Ergonul; Frederic Clayton; Agnes B Fogo; Donald E Kohan
Journal:  Pediatr Nephrol       Date:  2003-02-07       Impact factor: 3.714

7.  Risk factors for poor renal prognosis in children with hemolytic uremic syndrome.

Authors:  Alessandra Gianviti; Alberto E Tozzi; Laura De Petris; Alfredo Caprioli; Lucilla Ravà; Alberto Edefonti; Gianluigi Ardissino; Giovanni Montini; Graziella Zacchello; Alfonso Ferretti; Carmine Pecoraro; Tommaso De Palo; Angela Caringella; Maurizio Gaido; Rosanna Coppo; Francesco Perfumo; Nunzia Miglietti; Ilse Ratsche; Rosa Penza; Giovambattista Capasso; Silvio Maringhini; Salvatore Li Volti; Carmen Setzu; Marco Pennesi; Alberto Bettinelli; Leopoldo Peratoner; Ivana Pela; Elio Salvaggio; Giuliana Lama; Salvatore Maffei; Gianfranco Rizzoni
Journal:  Pediatr Nephrol       Date:  2003-10-31       Impact factor: 3.714

8.  Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Authors:  Richard L Siegler; Tom G Obrig; Theodore J Pysher; Vernon L Tesh; Nathaniel D Denkers; Fletcher B Taylor
Journal:  Pediatr Nephrol       Date:  2003-01-10       Impact factor: 3.714

9.  Binding of shiga toxin 2e to porcine erythrocytes in vivo and in vitro.

Authors:  Ilze Matise; Nancy A Cornick; James E Samuel; Harley W Moon
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Lisa Sartz; Anders Nelsson; Zivile D Békássy; Diana Karpman
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.